JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Young, L. H.
Right arrow Articles by Lefer, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Young, L. H.
Right arrow Articles by Lefer, A. M.

Vol. 295, Issue 1, 37-43, October 2000

Wortmannin, a Potent Antineutrophil Agent, Exerts Cardioprotective Effects in Myocardial Ischemia/Reperfusion1

Lindon H. Young2, Yasuhiko Ikeda3, Rosario Scalia and Allan M. Lefer

Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania

Ischemia followed by reperfusion in the presence of polymorphonuclear leukocytes (PMNs) results in a marked cardiac contractile dysfunction. Wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, suppresses superoxide production from PMNs. Therefore, we hypothesized that wortmannin could attenuate PMN-induced cardiac dysfunction by suppression of superoxide production from PMNs. We examined the effects of wortmannin in isolated ischemic (20 min) and reperfused (45 min) rat hearts perfused with PMNs. Wortmannin at 10, 20, or 40 nM given to hearts during the first 5 min of reperfusion, significantly improved left ventricular developed pressure (P < .01), and the maximal rate of development of left ventricular developed pressure (P < .01) compared with ischemic/reperfused hearts perfused with PMNs in the absence of wortmannin. In addition, wortmannin significantly reduced PMN infiltration into the myocardium by 50 to 75% (P < .001). Superoxide radical release also was significantly reduced in N-formylmethionyl-leucylphenylalanine-stimulated PMNs pretreated with 10 or 40 nM wortmannin by 70 and 95%, respectively (P < .001 versus untreated PMNs). Rat PMN adherence to rat superior mesenteric artery endothelium exposed to 2 U/ml thrombin was significantly attenuated by 10 to 40 nM wortmannin compared with untreated vessels (P < .001). These results provide evidence that wortmannin can significantly attenuate PMN-induced cardiac contractile dysfunction in the ischemic/reperfused rat heart via attenuation of PMN infiltration into the myocardium and suppression of superoxide release by PMNs.


1 This study was supported in part by Research Grant GM-45434 from the National Institute of General Medical Sciences of the National Institutes of Health.

2 L.H.Y. is a Postdoctoral Trainee of the National Heart, Lung, and Blood Institute of the National Institutes of Health (HL-07599).

3 Y.I. is a Research Fellow of the Japanese Society of Clinical Pharmacology and Therapeutics.


0022-3565/00/2951-0037$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Doukas, W. Wrasidlo, G. Noronha, E. Dneprovskaia, R. Fine, S. Weis, J. Hood, A. DeMaria, R. Soll, and D. Cheresh
Phosphoinositide 3-kinase {gamma}/{delta} inhibition limits infarct size after myocardial ischemia/reperfusion injury
PNAS, December 26, 2006; 103(52): 19866 - 19871.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Omiyi, R. J. Brue, P. Taormina II, M. Harvey, N. Atkinson, and L. H. Young
Protein Kinase C {beta}II Peptide Inhibitor Exerts Cardioprotective Effects in Rat Cardiac Ischemia/Reperfusion Injury
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 542 - 551.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Phillipson, E. E. Peterman, P. Taormina Jr., M. Harvey, R. J. Brue, N. Atkinson, D. Omiyi, U. Chukwu, and L. H. Young
Protein kinase C-{zeta} inhibition exerts cardioprotective effects in ischemia-reperfusion injury
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H898 - H907.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.